Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies Of Oral Lubiprostone To Treat Opioid-Induced Bowel Dysfunction (OBD)

Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and Takeda Pharmaceuticals North America, Inc. announced that the first patient has been enrolled in a Phase III study of lubiprostone (24 mcg, oral gel capsules, twice daily) for the treatment of Opioid-Induced Bowel Dysfunction (OBD). The OBD Pivotal Assessment of Lubiprostone (OPAL) program consists of two 12-week double-blind studies, followed by a nine-month open-label safety extension study. [click link for full article]

More: continued here

Filed under: GastroIntestinal / Gastroentorology on September 20th, 2007